Protocol Ledger

NCT06382948 · Phase III · RECRUITING

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

Interventional Phase III clinical trial protocol NCT06382948 sponsored by MedSIR in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-12-05 Enrollment: 300 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06382948
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)300 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06382948
Protocol FieldVerified Registry Value
NCT IdentifierNCT06382948
Consolidated Lead SponsorMedSIR
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment300 participants (ESTIMATED)
Registered Start Date2024-12-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06382948
Hospital Research SiteLocationSite Profile
Medical University of ViennaVienna, AustriaOpen Hospital Dossier ->
Centre Georges-François LeclercDijon, FranceOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI